Glioblastoma multiforme natural history: Difference between revisions
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
*[[Herniation]] ([[axial]], transtentorial, subfalcine, tonsillar) | *[[Herniation]] ([[axial]], transtentorial, subfalcine, tonsillar) | ||
*[[Systemic]] illness | *[[Systemic]] illness | ||
*[[Dysphagia]] | |||
*[[Aphasia]] | |||
*[[Brainstem]] invasion by [[tumor]] | *[[Brainstem]] invasion by [[tumor]] | ||
*Neutron-induced cerebral injury | *Neutron-induced cerebral injury | ||
*[[Weakness]] | |||
*[[Fatigue]] | |||
*[[Numbness]] | |||
*[[Surgical]] complications (cerebral [[hemorrhage]], [[edema]]) | *[[Surgical]] complications (cerebral [[hemorrhage]], [[edema]]) | ||
*[[Coma]] | |||
==Prognosis== | ==Prognosis== | ||
Revision as of 19:39, 14 September 2015
|
Glioblastoma multiforme Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Glioblastoma multiforme natural history On the Web |
|
American Roentgen Ray Society Images of Glioblastoma multiforme natural history |
|
Risk calculators and risk factors for Glioblastoma multiforme natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [3]
Overview
Natural History
Complications
Common complications of glioblastoma include:[1]
- Herniation (axial, transtentorial, subfalcine, tonsillar)
- Systemic illness
- Dysphagia
- Aphasia
- Brainstem invasion by tumor
- Neutron-induced cerebral injury
- Weakness
- Fatigue
- Numbness
- Surgical complications (cerebral hemorrhage, edema)
- Coma
Prognosis
- The median survival time from the time of diagnosis without any treatment is 3 months. Increasing age (> 60 years of age) carries a worse prognostic risk. Death is usually due to cerebral edema or increased intracranial pressure.
- With standard treatment (radiotherapy, chemotherapy (such as temozolomide), and surgery), the median survival is approximately 14 months.[2] Less than 10% of these patients survive past 5 years.
- A study published in 2007 reported the 2-year survival at 27.3%, 3-year survival 16.7% and 4 year survival 12.9%.[3]
References
- ↑ Silbergeld DL, Rostomily RC, Alvord EC (1991). "The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults". J Neurooncol. 10 (2): 179–85. PMID 1654403.
- ↑ Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M, Belanger K, Brandes A, Marosi C, Bogdahn U, Curschmann J, Janzer R, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Cairncross J, Eisenhauer E, Mirimanoff R (2005). "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma". N Engl J Med. 352 (10): 987–96. PMID 15758009.
- ↑ R. Mirimanoff , W. Mason , M. Van den Bent , R. Kortmann , M. Taphoorn , A. Brandes , S. Villa , G. Cairncrosss , T. Gorlia , R. Stupp International Journal of Radiation Oncology * Biology * Physics- November 2007 1 (Vol. 69, Issue 3, Page S2, DOI: 10.1016/j.ijrobp.2007.07.004) [1]